Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

被引：14

作者：

Moskowitz, Craig H. ^{[1
]}

Zinzani, Pier Luigi ^{[2
]}

Fanale, Michelle A. ^{[3
]}

Armand, Philippe ^{[4
]}

Johnson, Nathalie A. ^{[5
]}

Radford, John A. ^{[6
,7
]}

Ribrag, Vincent ^{[8
]}

Molin, Daniel ^{[9
]}

Vassilakopoulos, Theodoros P. ^{[10
]}

Tomita, Akihiro ^{[11
]}

von Tresckow, Bastian ^{[12
]}

Shipp, Margaret A. ^{[4
]}

Gustafson, Eric ^{[13
]}

Zhang, Yinghua ^{[13
]}

Ricart, Alejandro Daniel ^{[13
]}

Balakumaran, Arun ^{[13
]}

Chen, Robert W. ^{[14
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Jewish Gen Hosp, Montreal, PQ, Canada

[6] Univ Manchester, Manchester, Lancs, England

[7] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[8] Inst Gustave Roussy, Villejuif, France

[9] Uppsala Univ, Uppsala, Sweden

[10] Univ Athens, Laikon Gen Hosp, Athens, Greece

[11] Nagoya Univ Hosp, Nagoya, Aichi, Japan

[12] Univ Hosp Cologne, Cologne, Germany

[13] Merck & Co Inc, Kenilworth, NJ 07033 USA

[14] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1107.1107

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1107

引用

页数：7

共 50 条

[1] PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: MULTICOHORT, PHASE 2 KEYNOTE-087 STUDY
Moskowitz, C.
Zinzani, P. L.
Fanale, M. A.
Armand, P.
Johnson, N.
Ribrag, V.
Radford, J.
von Tresckow, B.
Tomita, A.
Shipp, M.
Wang, Y.
Ricart, A. D.
Balakumaran, A.
Chen, R.
HAEMATOLOGICA, 2016, 101 : 44 - 44
[2] MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087
Moskowitz, C.
Zinzani, P. L.
Fanale, M. A.
Armand, P.
Johnson, N.
Ribrag, V.
Radford, J.
von Tresckow, B.
Tomita, A.
Shipp, M. A.
Wang, Y.
Ricart, A. D.
Balakumaran, A.
Chen, R.
HAEMATOLOGICA, 2016, 101 : 319 - 319
[3] Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.
Chen, Robert W.
Zinzani, Pier Luigi
Fanale, Michelle A.
Armand, Philippe
Johnson, Nathalie
Ribrag, Vincent
Radford, John A.
Tomita, Akihiro
Shipp, Margaret Ann
Wang, Yang
Ricart, Alejandro Daniel
Balakumaran, Arun
Moskowitz, Craig H.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Chen, Robert
Zinzani, Pier Luigi
Lee, Hun Ju
Armand, Philippe
Johnson, Nathalie A.
Brice, Pauline
Radford, John
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
von Tresckow, Bastian
Shipp, Margaret A.
Lin, Jianxin
Kim, Eunhee
Nahar, Akash
Balakumaran, Arun
Moskowitz, Craig H.
BLOOD, 2019, 134 (14) : 1144 - 1153
[5] Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
Armand, Philippe
Zinzani, Pier Luigi
Lee, Hun Ju
Johnson, Nathalie A.
Brice, Pauline
Radford, John
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
von Tresckow, Bastian
Shipp, Margaret A.
Herrera, Alex F.
Lin, Jianxin
Kim, Eunhee
Chakraborty, Samhita
Marinello, Patricia
Moskowitz, Craig H.
BLOOD, 2023, 142 (10) : 878 - 886
[6] Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
von Tresckow, Bastian
Fanale, Michelle
Ardeshna, Kirit M.
Chen, Robert
Meissner, Julia
Morschhauser, Franck
Moskowitz, Craig
Zinzani, Pier Luigi
Giezek, Hilde
Balakumaran, Arun
Vo, Thao T.
Raut, Monika
Brice, Pauline
LEUKEMIA & LYMPHOMA, 2019, 60 (11) : 2705 - 2711
[7] Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
Zinzani, Pier Luigi
Lee, Hun Ju
Armand, Philippe
Johnson, Nathalie
Brice, Pauline
Radford, John
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
Von Tresckow, Bastian
Shipp, Margaret A.
Herrera, Alex F.
Lin, Jianxin
Kim, Eunhee
Farooqui, Mohammed
Marinello, Patricia
Moskowitz, Craig H.
BLOOD, 2019, 134
[8] Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)
Armand, Philippe
Zinzani, Pier Luigi Luigi
Lee, Hun Ju
Johnson, Nathalie
Brice, Pauline
Radford, John
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
von Tresckow, Bastian
Shipp, Margaret A.
Herrera, Alex F.
Lin, Jianxin
Kim, Eunhee
Chakraborty, Samhita
Marinello, Patricia
Moskowitz, Craig H.
BLOOD, 2021, 138
[9] Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis
Zinzani, Pier Luigi
Chen, Robert
Armand, Philippe
Johnson, Nathalie A.
Brice, Pauline
Radford, John
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
von Tresckow, Bastian
Shipp, Margaret A.
Lin, Jianxin
Nahar, Akash
Balakumaran, Arun
Moskowitz, Craig H.
LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 950 - 954
[10] Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification
Moskowitz, Craig H.
Chen, Robert W.
Armand, Philippe
Zinzani, Pier Luigi
Vassilakopoulos, Theodoros P.
Goldmacher, Gregory V.
Lin, Jianxin
Nahar, Akash
Balakumaran, Arun
Salles, Gilles
BLOOD, 2017, 130

← 1 2 3 4 5 →